Bioceltix SA (BCX) Price & Analysis

0 Followers

BCX Stock Chart & Stats

zł79.20

Market closed

zł79.20

Day’s Range― - ―

52-Week Rangezł70.00 - zł108.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)6.37K

Market Cap

zł422.66M

Enterprise Valuezł362.11

Total Cash (Recent Filing)zł60.79M

Total Debt (Recent Filing)zł235.30K

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Sep 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.32

Shares Outstanding5,532,253

10 Day Avg. Volume3,772

30 Day Avg. Volume6,367

Financial Highlights & Ratios

PEG Ratio3.36

Price to Book (P/B)5.29

Price to Sales (P/S)0.00

P/FCF Ratio-27.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)2.2

Revenue Forecast (FY)zł21.50M

BCX FAQ

What was Bioceltix SA’s price range in the past 12 months?

Bioceltix SA lowest stock price was zł70.00 and its highest was zł108.00 in the past 12 months.

What is Bioceltix SA’s market cap?

Bioceltix SA’s market cap is zł422.66M.

When is Bioceltix SA’s upcoming earnings report date?

Bioceltix SA’s upcoming earnings report date is Sep 23, 2026 which is in 8 days.

How were Bioceltix SA’s earnings last quarter?

Bioceltix SA released its earnings results on Apr 28, 2026. The company reported -zł1.026 earnings per share for the quarter.

Is Bioceltix SA overvalued?

According to Wall Street analysts Bioceltix SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioceltix SA pay dividends?

Bioceltix SA does not currently pay dividends.

What is Bioceltix SA’s EPS estimate?

Bioceltix SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioceltix SA have?

Bioceltix SA has 5,532,253 shares outstanding.

What happened to Bioceltix SA’s price movement after its last earnings report?

Bioceltix SA reported an EPS of -zł1.026 in its last earnings report. Following the earnings report the stock price went up 1.609%.

Which hedge fund is a major shareholder of Bioceltix SA?

Currently, no hedge funds are holding shares in PL:BCX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioceltix SA

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.